Form 4: Turn Therapeutics CFO Boosts Personal Stock Holdings

Turn Therapeutics' Interim CFO, Zuraiz Chaudhary, increased his direct ownership in the company's common stock through two separate open market purchases.

Summary

• Zuraiz Chaudhary, the Interim Chief Financial Officer, Vice President of Finance & Chief Accounting Officer of Turn Therapeutics Inc., acquired additional shares of the company's common stock.
• On November 20, 2025, Chaudhary purchased 1,450 shares of common stock at a price of $2.61 per share.
• On November 21, 2025, an additional 1,000 shares of common stock were purchased at a price of $3.29 per share.
• Following these transactions, Chaudhary's direct beneficial ownership of Turn Therapeutics Inc. common stock increased to 10,000 shares.
• These transactions were executed pursuant to a Rule 10b5-1(c) plan, indicating they were pre-arranged.

Sentiment

Score: 7

Explanation: The Interim CFO's decision to increase his personal stake in the company's common stock suggests a degree of confidence in the company's future prospects, which is generally viewed positively by the market.

Positives

• An insider, specifically the Interim CFO, is increasing their stake in the company, which can signal confidence in future performance and alignment with shareholder interests.
• The purchases were made at two different price points ($2.61 and $3.29), suggesting sustained buying interest from management.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Management Comments

• Zuraiz Chaudhary holds the positions of Interim Chief Financial Officer, Vice President of Finance & Chief Accounting Officer.

Industry Context

This filing reports an individual insider transaction and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders may interpret the insider buying as a positive signal of management's belief in the company's value and future performance.

Key Dates

Recommendation

While the Interim CFO's insider buying is a positive indicator of management confidence, the relatively modest transaction size and the absence of additional financial or strategic disclosures in this Form 4 do not provide sufficient new information to warrant a 'buy' recommendation. It reinforces a 'hold' position for existing investors and suggests continued monitoring for further company developments.

Keywords

Turn Therapeutics, TTRX, Insider Trading, Form 4, Stock Purchase, CFO, Beneficial Ownership, Equity Acquisition, Rule 10b5-1